Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Staphylococcus aureus
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Research== As of 2024, no approved [[vaccine]] exists against ''S. aureus''. Early [[clinical trial]]s have been conducted for several vaccines candidates such as Nabi's StaphVax and PentaStaph, [[Intercell|Intercell's]] / [[Merck & Co.|Merck's]] V710, VRi's SA75, and others.<ref>{{cite web|url=http://www.rff.org/files/sharepoint/WorkImages/Download/ETC-07.pdf |archive-url=https://web.archive.org/web/20160308211758/http://www.rff.org/files/sharepoint/WorkImages/Download/ETC-07.pdf |archive-date=2016-03-08 |url-status=live |title=A Shot Against MRSA?|publisher=Resources for the Future |date=20 April 2009 |access-date=7 October 2015}}</ref> While some of these vaccines candidates have shown immune responses, others aggravated an infection by ''S. aureus''. To date, none of these candidates provides protection against a ''S. aureus'' infection. The development of Nabi's StaphVax was stopped in 2005 after phase III trials failed.<ref>{{cite web|url=http://www.formatex.info/microbiology4/vol3/1911-1925.pdf |archive-url=https://web.archive.org/web/20151122163352/http://www.formatex.info/microbiology4/vol3/1911-1925.pdf |archive-date=2015-11-22 |url-status=live |title=Strengthening the immune system as an antimicrobial strategy against ''Staphylococcus aureus'' infections |publisher=FORMATEX RESEARCH CENTER |date=11 December 2013 |access-date=7 October 2015}}</ref> Intercell's first V710 vaccine variant was terminated during phase II/III after higher mortality and morbidity were observed among patients who developed ''S. aureus'' infection.<ref>{{cite web|url=http://www.news-medical.net/news/20110608/Intercell-Merck-terminate-V710-Phase-IIIII-trial-against-S-aureus-infection.aspx |title=Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection|publisher=Merck & Co. |date=8 June 2011 |access-date=7 October 2015}}</ref> Nabi's enhanced ''S. aureus'' vaccines candidate PentaStaph was sold in 2011 to GlaxoSmithKline Biologicals S.A.<ref>{{cite press release|url=http://globenewswire.com/news-release/2011/04/27/445328/219830/en/Nabi-Biopharmaceuticals-Completes-Final-PentaStaph-TM-Milestone.html |title=Nabi Biopharmaceuticals Completes Final PentaStaph(TM) Milestone |publisher=GLOBE NEWSWIRE |date=27 April 2011 |access-date=7 October 2015}}</ref> The current status of PentaStaph is unclear. A [[World Health Organization|WHO]] document indicates that PentaStaph failed in the phase III trial stage.<ref>{{cite web|url=https://www.who.int/immunization/research/forums_and_initiatives/4_OSchneewind_Staphylococcal_Vaccines_gvirf16.pdf |archive-url=https://web.archive.org/web/20160910053922/http://www.who.int/immunization/research/forums_and_initiatives/4_OSchneewind_Staphylococcal_Vaccines_gvirf16.pdf |archive-date=2016-09-10 |url-status=live |title=Vaccines to prevent antibiotic-resistant ''Staphylococcus aureus'' (MRSA)infections |publisher=University of Chicago |access-date=11 May 2017}}</ref> In 2010, [[GlaxoSmithKline]] started a [[Clinical trial#Phases|phase 1]] [[blinded experiment|blind study]] to evaluate its GSK2392103A vaccine.<ref name = "NCT01160172">{{ClinicalTrialsGov|NCT01160172|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults}}</ref> As of 2016, this vaccine is no longer under active development.<ref>{{cite web|url=http://www.nitag-resource.org/uploads/media/default/0001/03/041907310233c1d351cdc87ec952f56bd3abbed5.pdf |archive-url=https://web.archive.org/web/20161011140244/http://www.nitag-resource.org/uploads/media/default/0001/03/041907310233c1d351cdc87ec952f56bd3abbed5.pdf |archive-date=2016-10-11 |url-status=live |title=Status of vaccine research and development of vaccines for ''Staphylococcus aureus'' |publisher=Elsevier |date=19 April 2016 |access-date=10 October 2016}}</ref> [[Pfizer|Pfizer's]] ''S. aureus'' four-antigen vaccine SA4Ag was granted [[Fast track (FDA)|fast track designation]] by the U.S. [[Food and Drug Administration]] <!-- (FDA) --> in February 2014.<ref>{{cite web|url=http://www.pfizer.com/news/press-release/press-release-detail/pfizer_begins_phase_2b_study_of_its_investigational_multi_antigen_staphylococcus_aureus_vaccine_in_adults_undergoing_elective_spinal_fusion_surgery |title=Pfizer Begins Phase 2b Study of Its Investigational Multi-antigen ''Staphylococcus aureus'' Vaccine in Adults Undergoing Elective Spinal Fusion Surgery |publisher=Pfizer Inc. |date=7 July 2015 |access-date=24 February 2016}}</ref> In 2015, Pfizer has commenced a phase 2b trial regarding the SA4Ag vaccine.<ref name = "NCT02388165">{{ClinicalTrialsGov|NCT02388165|Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure (STRIVE)}}</ref> Phase 1 results published in February 2017 showed a very robust and secure immunogenicity of SA4Ag.<ref name="pmid28143674">{{cite journal | vauthors = Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A | title = SA4Ag, a 4-antigen ''Staphylococcus aureus'' vaccine, rapidly induces high levels of bacteria-killing antibodies | journal = Vaccine | volume = 35 | issue = 8 | pages = 1132ā9 | date = February 2017 | pmid = 28143674 | doi = 10.1016/j.vaccine.2017.01.024 | doi-access = free }}</ref> The vaccine underwent clinical trial until June 2019, with results published in September 2020, that did not demonstrate a significant reduction in Postoperative Bloodstream Infection after Surgery.<ref name = "NCT02388165" /> In 2015, Novartis Vaccines and Diagnostics, a former division of [[Novartis]] and now part of GlaxoSmithKline, published promising pre-clinical results of their four-component ''Staphylococcus aureus'' vaccine, 4C-staph.<ref name="pmid26015481">{{cite journal | vauthors = Torre A, Bacconi M, Sammicheli C, Galletti B, Laera D, Fontana MR, Grandi G, De Gregorio E, Bagnoli F, Nuti S, Bertholet S, Bensi G | title = Four-component ''Staphylococcus aureus'' vaccine 4C-staph enhances Fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice | journal = Infection and Immunity | volume = 83 | issue = 8 | pages = 3157ā63 | date = August 2015 | pmid = 26015481 | pmc = 4496606 | doi = 10.1128/IAI.00258-15 }}</ref> In addition to vaccine development, research is being performed to develop alternative treatment options that are effective against antibiotic resistant strains including MRSA. Examples of alternative treatments are [[phage therapy]], [[antimicrobial peptides]] and [[Host-directed therapeutics|host-directed therapy]].<ref>{{cite journal | vauthors = Scheper H, Wubbolts JM, Verhagen JA, de Visser AW, van der Wal RJ, Visser LG, de Boer MG, Nibbering PH | title = SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection | journal = Frontiers in Microbiology | volume = 12 | pages = 625952 | date = 2021-01-29 | pmid = 33584628 | pmc = 7879538 | doi = 10.3389/fmicb.2021.625952 | doi-access = free }}</ref><ref>{{cite journal | vauthors = van den Biggelaar RH, Walburg KV, van den Eeden SJ, van Doorn CL, Meiler E, de Ries AS, Meijer AH, Ottenhoff TH, Saris A | title = Identification of kinase modulators as host-directed therapeutics against intracellular methicillin-resistant ''Staphylococcus aureus'' | journal = Frontiers in Cellular and Infection Microbiology | volume = 14 | pages = 1367938 | date = 2024 | pmid = 38590439 | pmc = 10999543 | doi = 10.3389/fcimb.2024.1367938 | doi-access = free }}</ref> ===Standard strains=== A number of standard strains of ''S. aureus'' (called "type cultures") are used in research and in laboratory testing, such as: {| class="wikitable" style="text-align: left;" |+ Standard strains of ''Staphylococcus aureus'' |- ! Name ! NCTC ! ATCC ! Year of deposit ! Comment |- | Oxford H || 6571 || 9144 || 1943 || Standard strain used for testing penicillin potency and by which the penicillin unit was originally defined.<ref>{{cite journal | vauthors = Mayr-Harting A | title = The acquisition of penicillin resistance by ''Staphylococcus aureus'', strain Oxford | journal = Journal of General Microbiology | volume = 13 | issue = 1 | pages = 9ā21 | date = August 1955 | pmid = 13252206 | doi = 10.1099/00221287-13-1-9 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Kearns AM, Ganner M, Holmes A | title = The 'Oxford Staphylococcus': a note of caution | journal = The Journal of Antimicrobial Chemotherapy | volume = 58 | issue = 2 | pages = 480ā1 | date = August 2006 | pmid = 16735421 | doi = 10.1093/jac/dkl230 }}</ref> |- | Rosenbach || 12973 || 29213 || 1884 || Standard strain for EUCAST antimicrobial resistance testing.<ref>{{cite book | author = EUCAST | title = Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST: version 10.0 | url = https://eucast.org/ast_of_bacteria/quality_control/ | location = VƤxjƶ, Sweden | publisher = European Society of Clinical Microbiology and Infectious Diseases | date = 2020-01-01 | page = 9 }}</ref> |}
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)